TY - JOUR
T1 - Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia
T2 - A pilot study
AU - Boyer, Holly
AU - Fernandes, Patricia
AU - Duran, Olga
AU - Hunter, David
AU - Goding, George
PY - 2011/7
Y1 - 2011/7
N2 - Background: The aim of this pilot study is to evaluate office-based sclerotherapy using sodium tetradecyl sulfate (STS) for epistaxis due to hereditary hemorrhagic telangiectasias (HHT). Patients with HHT suffer from unpredictable, recurrent, severe nasal bleeding necessitating emergency care, nasal packing, blood transfusions, and invasive procedures. Methods: In this retrospective study 7 patients with a history of treatment for recurrent epistaxis due to HHT were treated in an office-based setting with intralesional injection of STS. Treatment results were evaluated using a questionnaire. All patients had undergone multiple prior procedures attempting to control epistaxis. Results: Patients had an average of 5 sclerotherapy treatments for HHT. Patients were treated using topical and/or local anesthesia with no reports of discomfort. Bleeding requiring intervention did not occur during the procedures. After the procedure all patients (100%) reported significantly less frequent and less severe nasal bleeding. A total of 83% reported that their need for nasal packing was reduced. All patients were willing to undergo the same treatment again. No complications such as perforation, crusting, or foul smell were reported. Conclusion: This is the first clinical experience demonstrating that office-based sclerotherapy with STS is a safe, tolerable, and useful alternative for the treatment of epistaxis due to HHT.
AB - Background: The aim of this pilot study is to evaluate office-based sclerotherapy using sodium tetradecyl sulfate (STS) for epistaxis due to hereditary hemorrhagic telangiectasias (HHT). Patients with HHT suffer from unpredictable, recurrent, severe nasal bleeding necessitating emergency care, nasal packing, blood transfusions, and invasive procedures. Methods: In this retrospective study 7 patients with a history of treatment for recurrent epistaxis due to HHT were treated in an office-based setting with intralesional injection of STS. Treatment results were evaluated using a questionnaire. All patients had undergone multiple prior procedures attempting to control epistaxis. Results: Patients had an average of 5 sclerotherapy treatments for HHT. Patients were treated using topical and/or local anesthesia with no reports of discomfort. Bleeding requiring intervention did not occur during the procedures. After the procedure all patients (100%) reported significantly less frequent and less severe nasal bleeding. A total of 83% reported that their need for nasal packing was reduced. All patients were willing to undergo the same treatment again. No complications such as perforation, crusting, or foul smell were reported. Conclusion: This is the first clinical experience demonstrating that office-based sclerotherapy with STS is a safe, tolerable, and useful alternative for the treatment of epistaxis due to HHT.
KW - Epistaxis
KW - Hereditary hemorrhagic telangiectasia
KW - Osler-Weber-Rendu syndrome
KW - Sclerotherapy
KW - Sodium tetradecyl sulfate
UR - http://www.scopus.com/inward/record.url?scp=84861162862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861162862&partnerID=8YFLogxK
U2 - 10.1002/alr.20053
DO - 10.1002/alr.20053
M3 - Article
C2 - 22287439
AN - SCOPUS:84861162862
SN - 2042-6976
VL - 1
SP - 319
EP - 323
JO - International Forum of Allergy and Rhinology
JF - International Forum of Allergy and Rhinology
IS - 4
ER -